The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Immune Checkpoint Inhibitor-Associated Myocarditis
Open accessAbstract
Immune checkpoint inhibitors (ICIs) are approved for a wide range of malignancies. They work by priming the immune system response to cancer and have changed the landscape of available cancer treatments. As anticipated, modulation of the regulatory controls in the immune system with ICIs results in diverse immune-related adverse events, targeting any organ or gland. These toxicities are rarely fatal and generally regress after treatment discontinuation and/or prescription of corticosteroids. Recently, several cases of ICI-related cardiotoxicity have been reported with complications ranging from cardiogenic shock to sudden death. The true incidence of ICI-associated myocarditis is likely underestimated, due to a combination of factors including the lack of specificity in the clinical presentation, the potential of overlap with other cardiovascular and general medical illnesses, the challenges in the diagnosis, and a general lack of awareness of this condition. Currently, there are no clear guidelines for surveillance, diagnosis, or management of this entity. There are multiple unresolved issues including, but not limited to, identifying those at risk of this uncommon toxicity, elucidating the pathophysiology, determining if and what type of surveillance is appropriate, optimal work-up of suspected patients, and methods for resolution of myocarditis. Here we describe a clinical vignette and discuss the salient features and management strategies of ICI-associated myocarditis. Key Points: The incidence of immune checkpoint inhibitor (ICI)-associated myocarditis is unclear and has been reported to range from 0.06% to 1% of patients prescribed an ICI. Myocarditis may be difficult to diagnose. The risk factors for ICI-associated myocarditis are not well understood but may include underlying autoimmune disease and diabetes mellitus. The prevalence of myocarditis has been reported to be higher with combination immune therapies. Myocarditis with ICI's typically occurs early, with an elevated troponin, may present with an normal left ventricular ejection fraction and may have a fulminant course. The optimal management of myocarditis associated with ICI's is unclear but most cases are treated with high-dose steroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper
Friedrich, M. G., Sechtem, U., Schulz-Menger, J., Holmvang, G., Alakija, P., Cooper, L. T., White, J. A., Abdel-Aty, H., Gutberlet, M., Prasad, S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.007 · Cited by 2,509
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Self-citationToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Mahrholdt, H., Goedecke, C., Wagner, A., Meinhardt, G., Athanasiadis, A., Vogelsberg, H., Fritz, P., Klingel, K., Kandolf, R., & Sechtem, U. (2004) · Circulation · doi:10.1161/01.cir.0000118493.13323.81 · Cited by 1,030
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817
Abdel-Aty, H., Boyé, P., Zagrosek, A., Wassmuth, R., Kumar, A., Messroghli, D., Bock, P., Dietz, R., Friedrich, M. G., & Schulz-Menger, J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.11.069 · Cited by 770
Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., et al. (2003) · Nature Medicine · doi:10.1038/nm955 · Cited by 689
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity
Escudier, M., Cautela, J., Malissen, N., Ancedy, Y., Orabona, M., Pinto, J., Monestier, S., Grob, J.-J., Scemama, U., Jacquier, A., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.030571 · Cited by 517
Comprehensive analysis of the clinical immuno-oncology landscape
Tang, J., Shalabi, A., & Hubbard-Lucey, V. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx755 · Cited by 508
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
Kwon, H. J., Cot, T. R., Cuffe, M. S., Kramer, J. M., & Braun, M. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00008 · Cited by 455
Schadendorf, D., Wolchok, J. D., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Chesney, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2289 · Cited by 441
HAUCK, A. J., KEARNEY, D. L., & EDWARDS, W. D. (1989) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61286-5 · Cited by 437
Cardiac MR With Late Gadolinium Enhancement in Acute Myocarditis With Preserved Systolic Function
Aquaro, G. D., Perfetti, M., Camastra, G., Monti, L., Dellegrottaglie, S., Moro, C., Pepe, A., Todiere, G., Lanzillo, C., Scatteia, A., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.044 · Cited by 435
Gräni, C., Eichhorn, C., Bière, L., Murthy, V. L., Agarwal, V., Kaneko, K., Cuddy, S., Aghayev, A., Steigner, M., Blankstein, R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.050 · Cited by 426
Pollack, M. H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A. S., Ancell, K. K., Long, G. V., Menzies, A. M., Eroglu, Z., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx642 · Cited by 393
Report from a consensus conference on antibody-mediated rejection in heart transplantation
Kobashigawa, J., Crespo-Leiro, M. G., Ensminger, S. M., Reichenspurner, H., Angelini, A., Berry, G., Burke, M., Czer, L., Hiemann, N., Kfoury, A. G., et al. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.11.003 · Cited by 368
Immune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339
Kobashigawa, J. A., Miller, L. W., Russell, S. D., Ewald, G. A., Zucker, M. J., Goldberg, L. R., Eisen, H. J., Salm, K., Tolzman, D., Gao, J., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01290.x · Cited by 329
Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8 + T-Cell–Mediated Injury in the Heart
Grabie, N., Gotsman, I., DaCosta, R., Pang, H., Stavrakis, G., Butte, M. J., Keir, M. E., Freeman, G. J., Sharpe, A. H., & Lichtman, A. H. (2007) · Circulation · doi:10.1161/circulationaha.107.709360 · Cited by 288
Smoldering myocarditis following immune checkpoint blockade
Norwood, T. G., Westbrook, B. C., Johnson, D. B., Litovsky, S. H., Terry, N. L., McKee, S. B., Gertler, A. S., Moslehi, J. J., & Conry, R. M. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0296-4 · Cited by 201
Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw141 · Cited by 177
Definition of Inflammatory Cardiomyopathy (Myocarditis): On the Way to Consensus
Maisch, B., Portig, I., Ristic, A., Hufnagel, G., & Pankuweit, S. (2000) · Herz · doi:10.1007/s000590050007 · Cited by 170
Rodriguez, E. R., Skojec, D. V., Tan, C. D., Zachary, A. A., Kasper, E. K., Conte, J. V., & Baldwin, W. M. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01074.x · Cited by 162
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 162
Self-citationFarhad, H., Staziaki, P. V., Addison, D., Coelho‐Filho, O. R., Shah, R. V., Mitchell, R. N., Szilveszter, B., Abbasi, S. A., Kwong, R. Y. K., Scherrer‐Crosbie, M., et al. (2016) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.115.003584 · Cited by 118
Self-citationImmune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
Suozzi, K. C., Stahl, M. F., Ko, C. J., Chiang, A. C., Gettinger, S. N., Siegel, M. D., & Bunick, C. G. (2016) · JAAD Case Reports · doi:10.1016/j.jdcr.2016.05.002 · Cited by 101
Love, V. A., Grabie, N., Duramad, P., Stavrakis, G., Sharpe, A. H., & Lichtman, A. H. (2007) · Circulation Research · doi:10.1161/circresaha.106.147124 · Cited by 97
Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab
Reuben, A., de Macêdo, M. P., McQuade, J. L., Joon, A. Y., Ren, Z., Calderone, T. L., Conner, B., Wani, K., Cooper, Z. A., Tawbi, H. A., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1361097 · Cited by 74
Serial Electrocardiographic Findings in Acute Myocarditis.
Nakashima, H., Honda, Y., & Katayama, T. (1994) · Internal Medicine · doi:10.2169/internalmedicine.33.659 · Cited by 62
Santini, F. C., Rizvi, H. A., Wilkins, O., van Voorthuysen, M., Panora, E., Halpenny, D. F., Kris, M. G., Rudin, C. M., Chaft, J. E., & Hellmann, M. D. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9012 · Cited by 52
Berg, D. D., Vaduganathan, M., Davids, M. S., Alyea, E. P., Torre, M., Padera, R. F., & Nohria, A. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.806 · Cited by 51
Ogawa, T., Veinot, J. P., de Bold, M. L. K., Georgalis, T., & de Bold, A. J. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00215.2008 · Cited by 41
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,364
Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab674 · Cited by 645
Self-citationNCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 485
Metadata
- Authors
- Ganatra, S., & Neilan, T. G.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-25
- Volume
- 23
- Issue
- 8
- Pages
- 879-886
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2804734521
- Cited by
- 299
- References
- 42
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.